To L B, Haylock D N, Dowse T, Simmons P J, Trimboli S, Ashman L K, Juttner C A
Leukaemia Research Unit, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, Australia.
Blood. 1994 Nov 1;84(9):2930-9.
Peripheral blood (PB) CD34+ cells from four commonly used mobilization protocols were studied to compare their phenotype and proliferative capacity with steady-state PB or bone marrow (BM) CD34+ cells. Mobilized PB CD34+ cells were collected during hematopoietic recovery after myelosuppressive chemotherapy with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) or during G-CSF administration alone. The expression of activation and lineage-associated markers and c-kit gene product were studied by flow cytometry. Proliferative capacity was measured by generation of nascent myeloid progenitor cells (granulocyte-macrophage colony-stimulating factor; CFU-GM) and nucleated cells in a stroma-free liquid culture stimulated by a combination of six hematopoietic growth factors (interleukin-1 (IL-1), IL-3, IL-6, GM-CSF, G-CSF, and stem cell factor). G-CSF-mobilized CD34+ cells have the highest percentage of CD38- cells (P < .0081), but otherwise, CD34+ cells from different mobilization protocols were similar to one another in their phenotype and proliferative capacity. The spectrum of primitive and mature myeloid progenitors in mobilized PB CD34+ cells was similar to their steady-state counterparts, but the percentages of CD34+ cells expressing CD10 or CD19 were lower (P < .0028). Although steady-state PB and chemotherapy-mobilized CD34+ cells generated fewer CFU-GM at day 21 than G-CSF-mobilized and steady-state BM CD34+ cells (P < .0449), the generation of nucleated cells and CFU-GM were otherwise comparable. The presence of increased or comparable numbers of hematopoietic progenitors within PB collections with equivalent proliferative capacity to BM CD34+ cells is not unexpected given the rapid and complete hematopoietic reconstitution observed with mobilized PB. However, all four types of mobilized PB CD34+ cells are different from steady-state BM CD34+ cells in that they express less c-kit (P < .0002) and CD71 (P < .04) and retain less rhodamine 123 (P < .0001). These observations are novel and suggest that different mobilization protocols may act via similar pathways involving the down-regulation of c-kit and may be independent of cell-cycle status.
研究了来自四种常用动员方案的外周血(PB)CD34+细胞,以比较它们与稳态PB或骨髓(BM)CD34+细胞的表型和增殖能力。动员的PB CD34+细胞在骨髓抑制化疗后造血恢复期间收集,化疗时使用或不使用粒细胞-巨噬细胞集落刺激因子(GM-CSF)或粒细胞集落刺激因子(G-CSF),或单独使用G-CSF期间收集。通过流式细胞术研究激活和谱系相关标志物以及c-kit基因产物的表达。通过在由六种造血生长因子(白细胞介素-1(IL-1)、IL-3、IL-6、GM-CSF、G-CSF和干细胞因子)组合刺激的无基质液体培养中产生新生髓系祖细胞(粒细胞-巨噬细胞集落刺激因子;CFU-GM)和成核细胞来测量增殖能力。G-CSF动员的CD34+细胞中CD38-细胞的百分比最高(P < 0.0081),但除此之外,来自不同动员方案的CD34+细胞在表型和增殖能力上彼此相似。动员的PB CD34+细胞中原始和成熟髓系祖细胞的谱系与它们的稳态对应物相似,但表达CD10或CD19的CD34+细胞百分比更低(P < 0.0028)。尽管稳态PB和化疗动员的CD34+细胞在第21天时产生的CFU-GM比G-CSF动员的和稳态BM CD34+细胞少(P < 0.0449),但成核细胞和CFU-GM的产生在其他方面是可比的。考虑到动员的PB观察到的快速和完全造血重建,PB采集中存在数量增加或与BM CD34+细胞增殖能力相当的造血祖细胞并不意外。然而,所有四种类型的动员PB CD34+细胞与稳态BM CD34+细胞不同,因为它们表达较少的c-kit(P < 0.0002)和CD71(P < 0.04),并且保留较少的罗丹明123(P < 0.0001)。这些观察结果是新颖的,表明不同的动员方案可能通过涉及c-kit下调的相似途径起作用,并且可能与细胞周期状态无关。